Resources

The World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization concluded that a single dose of human papillomavirus (HPV) vaccine delivers solid protection against HPV. Based on the available evidence, SAGE advised that countries may now choose between a one- or two-dose schedule for 9–14-year-old girls and women aged 15 to 20. This is a major step toward reaching the WHO’s global strategy to accelerate the elimination of cervical cancer.This two-page brief a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

PATH actively engages in developing, introducing, and scaling evidence–based self–testing technologies and approaches in low– and middle–income countries. Our comprehensive approach connects research and development efforts with practical deployment interventions, as countries respond to disease and health system challenges by expanding self–testing. We integrate self–test data into digital health systems, facilitate the commercialization of diagnostics tailored to end users, and provide vital support to bolster local primary health care systems.

This document describes minimally acceptable and optimal targets for a prophylactic HPV microarray patch (MAP)—dissolving and solid–coated—which is currently in early–stage preclinical development. Although the goal of PATH’s MAP Center of Excellence is focused on advancing the MAP technology platform for high–priority needs in low– and middle–income countries (LMICs), a product with a dual market is more sustainable and could reduce costs in LMIC markets. Therefore, this target product profile describes a global product driven by the needs of LMICs that would also benefit users in high–income countries. Ideally, an HPV MAP product could be suitable for both markets with minimal differences. Key targets that would differ between LMIC and high–income countries contexts are defined. Parameters that will be critical for the success of using a MAP to deliver a prophylactic HPV vaccine include the intended use case, schedule, breadth of protection, and use of adjuvants. The target product profile will serve as a living document that will benefit from stakeholder input and evolve over time as new data are generated.

In India, addressing tuberculosis (TB) requires collaboration, particularly within the private health care sector, where a substantial number of TB cases remain undiagnosed or receive insufficient treatment. Recognizing this challenge, our TB public–private mix compendium serves as a resource, documenting progress in private sector engagement for over two decades. It's an essential tool for stakeholders committed to refining TB control strategies, providing practical insights into the private sector's role in reshaping the narrative of TB control, and addressing this health concern in India.

Improving access to tools that enable providers to deliver more accurate and integrated screening, diagnosis, and care.